Press Releases
Isis Pharmaceuticals to Present at Upcoming Investor Conferences
- 24th Annual
Credit Suisse Healthcare Conference onWednesday, November 11, 2015 inScottsdale, AZ ; - 2015
Stifel Healthcare Conference onWednesday, November 18, 2015 inNew York, NY ; and - 27th Annual
Piper Jaffray Healthcare Conference onTuesday, December 1, 2015 inNew York, NY .
The above listed dates are subject to change. Details on presentation times or changes to presentation dates can be found on the Company's website. Please check www.isispharm.com for the latest information.
A live webcast of the presentations will be available on the "Investors & Media" section of the Isis website. The replays will be available within 48 hours and will be archived for a limited time.
ABOUT
Isis is the leading company in RNA-targeted drug discovery and development focused on developing drugs for patients who have the highest unmet medical needs, such as those patients with severe and rare diseases. Using its proprietary antisense technology, Isis has created a large pipeline of first-in-class or best-in-class drugs, with over a dozen drugs in mid- to late-stage development. Drugs currently in Phase 3 development include volanesorsen, a drug Isis is developing and plans to commercialize through its wholly owned subsidiary, Akcea Therapeutics, to treat patients with familial chylomicronemia syndrome and familial partial lipodystrophy; ISIS-TTRRx, a drug Isis is developing with GSK to treat patients with all forms of TTR amyloidosis; and ISIS-SMNRx, a drug Isis is developing with Biogen to treat infants and children with spinal muscular atrophy. Isis' patents provide strong and extensive protection for its drugs and technology. Additional information about Isis is available at www.isispharm.com.
This press release includes forward-looking statements regarding
Logo - http://photos.prnewswire.com/prnh/20130807/LA60006LOGO
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/isis-pharmaceuticals-to-present-at-upcoming-investor-conferences-300173714.html
SOURCE
D. Wade Walke, Ph.D., Vice President, Corporate Communications and Investor Relations, 760-603-2741, Amy Williford, Ph.D., Associate Director, Corporate Communications, 760-603-2772